Composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss comprising lilium lancifolium extract as active ingredient

Abstract

The present invention relates to a composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss, comprising a Lilium lancifolium extract as an active ingredient. Specifically, when C2C12 cells were pre-treated with a Lilium lancifolium extract, and then treated with H2O2, dexamethasone, or TNF-α, muscle damage was alleviated and muscle loss was inhibited, and the muscle mass and grip strength decreased by dexamethasone administration in a muscle atrophy mouse model were increased upon administration of the Lilium lancifolium extract. Therefore, the composition can be effectively used as a health functional food, medicine or feed additive for strengthening muscle strength or preventing, ameliorating or treating muscle loss.

Description

A composition for strengthening muscle or preventing, improving or treating muscle loss, containing lily extract as an active ingredient

[0001] The present invention relates to a composition for strengthening muscle or preventing, improving or treating muscle loss, comprising a lily extract as an active ingredient.

[0002]

[0003] This work was carried out with the support of the Ministry of Science and ICT's major projects (Project Number: 1711195901).

[0004] Our body's muscles attach to bones and perform various functions, including protecting them and maintaining proper body shape. Muscles also promote calcium influx, increasing bone density. However, as the body ages, changes in composition lead to a redistribution of body fat and protein. Human muscle mass gradually declines after age 40, with a 50% loss of maximum muscle mass by age 80. Muscle loss in old age is recognized as the most significant factor in declining overall physical function. As we age, changes in body shape, such as muscle and fat content and skeletal distortion, become more noticeable. The prevalence of obesity due to sarcopenia in old age continues to rise, reaching over 30% worldwide. Furthermore, abnormal insulin secretion can impede the proper supply of energy to cells, leading to muscle development disorders, making sarcopenia more prevalent in diabetic patients than in the general population. Muscle loss increases the risk of arthritis, back pain, and chronic pain. It can also worsen urinary incontinence caused by abdominal obesity. Furthermore, fractures can increase depression in later life and even lead to death. Therefore, sarcopenia in older adults not only harms mental health but is also linked to chronic diseases associated with the elderly, making it a major cause of a decline in quality of life. Because it is closely related to these chronic diseases, muscle strengthening, muscle augmentation, muscle differentiation, muscle regeneration, or the prevention, improvement, or treatment of sarcopenia can help curb the decline in physical activity due to aging.

[0005] The global market for treatments for progressive ataxia and muscle weakness reached approximately $14 billion in 2011. While treatments for sarcopenia include increasing mitochondrial production, inhibiting muscle protein breakdown, and anti-inflammatory drugs, there are currently no proven treatments. Furthermore, the recommended dietary approach to prevent sarcopenia in the elderly suggests consuming 25-30 grams of high-quality protein per meal. This equates to consuming 4-5 eggs or approximately 120 grams of chicken breast per meal, making it difficult for the average person to achieve this goal. Consequently, many people are turning to protein supplements as an alternative, but these supplements can lead to excessive protein intake and potentially harmful side effects. Furthermore, kidney disease precludes a high-protein diet, and kidney function declines with age. Therefore, alternatives to high-protein intake are necessary to prevent sarcopenia.

[0006] Meanwhile, the lily (Lilium lancifolium) is a plant belonging to the lily family and is also called the tiger lily (Easter lily). It is mainly distributed in continental cool-temperate climates to warm-temperate climates, and grows in the eastern part of the Eurasian continent, including Korea, Japan, China, and Manchuria. It is a perennial plant that lives by taking root in crevices of rocks, crevices of embankments, and crevices of rocks in mountain streams that are difficult for people to access.

[0007] As prior art related to muscle diseases, Korean Patent No. 2354289 discloses a composition for preventing, improving, or treating muscle diseases containing a fantail extract as an active ingredient, and Korean Patent Publication No. 2023-0136446 discloses a composition for preventing or treating muscle diseases containing a wormwood extract as an active ingredient. However, no composition for strengthening muscle strength or preventing, improving, or treating muscle loss containing the lily extract of the present invention as an active ingredient has been disclosed to date.

[0008] The present invention was derived from the above-mentioned needs, and relates to a composition for strengthening muscle strength or preventing, improving, or treating muscle loss, which contains a lily extract as an active ingredient. Specifically, when C2C12 cells were pretreated with a lily (Lilium lancifolium) extract and then treated with H2O2, dexamethasone, and TNF-α, respectively, muscle damage was alleviated and muscle loss was suppressed, and in a muscular atrophy mouse model, muscle mass and grip strength decreased by dexamethasone administration were confirmed to be increased by administration of the lily extract, thereby completing the present invention.

[0009] To achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating muscle disease, which comprises a lily extract as an active ingredient.

[0010] In addition, the present invention provides a health functional food composition for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss, which contains a lily extract as an effective ingredient.

[0011] In addition, the present invention provides a veterinary composition for preventing or treating muscle disease, which comprises a lily extract as an active ingredient.

[0012] In addition, the present invention provides a feed additive for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss, which contains a lily extract as an effective ingredient.

[0013] In addition, the present invention provides a herbal medicine composition for preventing or treating muscle disease, which contains a lily extract as an active ingredient.

[0014] The present invention relates to a composition for strengthening muscle strength or preventing, improving or treating muscle loss, comprising a lily extract as an active ingredient. Specifically, when C2C12 cells were pretreated with a lily (Lilium lancifolium) extract and then treated with H2O2, dexamethasone and TNF-α, respectively, muscle damage was alleviated and muscle loss was suppressed, and in a muscular atrophy mouse model, muscle mass and grip strength decreased by dexamethasone administration were increased by administration of the lily extract.

[0015] Figure 1 shows the results of measuring cell survival rate when the lily extract of the present invention was treated at various concentrations to mouse myoblasts (C2C12).

[0016] Figure 2 shows the results of measuring cell viability when mouse myoblasts (C2C12) were pretreated with the lily extract of the present invention at various concentrations and then treated with (A) H2O2, (B) DEX (dexamethasone), and (C) TNF-α, which induce muscle damage. C is the normal group that was not treated with anything. **, *** indicate that the cell viability of the groups treated with H2O2, DEX, or TNF-α alone was statistically significantly decreased compared to the normal group. ** is p<0.01, and *** is p<0.001. #, ##, ### indicate that the cell viability of the groups treated with the lily extract of the present invention was statistically significantly increased compared to the groups treated with H2O2, DEX, or TNF-α alone. # is p<0.05, ## is p<0.01, and ### is p<0.001.

[0017] Figure 3 shows the morphological changes in myotube cells (A) and the graph quantifying them (B) when C2C12 myotube cells were pretreated with the lily extract of the present invention at various concentrations and then treated with H2O2, which induces muscle damage. Control (C) is the normal group that was not treated with anything. *** indicates that the myotube cell density of the H2O2-only treated group was statistically significantly decreased compared to the normal group, and p<0.001. ### indicates that the myotube cell density of the lily extract treated group of the present invention was statistically significantly increased compared to the H2O2-only treated group, and p<0.001.

[0018] Figure 4 shows the results of confirming the morphological changes of myotube cells (A) and myotube density (B) when C2C12 myotube cells were pretreated with the lily extract of the present invention at various concentrations and then treated with dexamethasone (DEX), which induces muscle damage. Control (C) is the normal group that was not treated with anything. *** indicates that the myotube cell density of the DEX only treatment group was statistically significantly decreased compared to the normal group, and p<0.001. ### indicates that the myotube cell density of the lily extract treatment group of the present invention was statistically significantly increased compared to the DEX only treatment group, and p<0.001.

[0019] Figure 5 shows the morphological changes in myotube cells (A) and the graph quantifying them (B) when C2C12 myotube cells were pretreated with the lily extract of the present invention at various concentrations and then treated with TNF-α, which induces muscle damage. Control (C) is the normal group that was not treated with anything. *** indicates that the density of myotube cells in the TNF-α only treatment group was statistically significantly decreased compared to the normal group, and p<0.001. #, ### indicate that the density of myotube cells in the lily extract treatment group of the present invention was statistically significantly increased compared to the TNF-α only treatment group, and # indicates p<0.05 and ### indicates p<0.001.

[0020] Figure 6 shows the results of confirming the change in grip strength of experimental animals according to administration of the lily extract of the present invention in a dexamethasone-induced muscular dystrophy animal model. *** indicates that the grip strength of the dexamethasone-only administration group statistically significantly decreased compared to the untreated normal group, p<0.001. ### indicates that the grip strength of the lily extract administration group or the positive control group (resveratrol, Rsv) statistically significantly increased compared to the dexamethasone-only administration group, p<0.001.

[0021] Figure 7 shows the results of confirming the changes in muscle mass of (A) tibialis anterior (TA) and (B) gastrocnemius (GA) muscle according to administration of the lily extract of the present invention in a dexamethasone-induced muscular dystrophy animal model. *** indicates that the TA or GA muscle mass of the dexamethasone-only administered group was statistically significantly decreased compared to the untreated normal group, and p<0.001. ### indicates that the TA or GA muscle mass of the lily extract-administered group or the positive control group (resveratrol, Rsv) was statistically significantly increased compared to the dexamethasone-administered group, and p<0.001.

[0022] Figure 8 shows the results of confirming the change in muscle fiber cross-sectional area (CSA) according to administration of the lily extract of the present invention in an animal model of muscular dystrophy induced by dexamethasone. Control is a normal group that was not treated with anything. *** indicates that the muscle fiber cross-sectional area (CSA) of the dexamethasone-only administered group was statistically significantly decreased compared to the normal group that was not treated with anything, and p<0.001. ### indicates that the muscle fiber cross-sectional area (CSA) of the lily extract-administered group or the positive control group (resveratrol, Rsv) was statistically significantly increased compared to the dexamethasone-only administered group, and p<0.001.

[0023] In order to achieve the purpose of the present invention, the present invention also provides a pharmaceutical composition for preventing or treating muscle disease, which comprises a lily (Lilium lancifolium) extract as an active ingredient.

[0024] The above lily extract may be prepared by a method including, but not limited to, the following steps:

[0025] 1) A step of extracting lilies by adding an extraction solvent;

[0026] 2) a step of filtering the extract of step 1); and

[0027] 3) A step of producing an extract by concentrating and drying the filtered extract of step 2) under reduced pressure.

[0028] In the above step 1), the extraction solvent is preferably water, a lower alcohol of C1 to C4, or a mixture thereof, more preferably ethanol, but is not limited thereto.

[0029] In the above manufacturing method, the extraction method may be any conventional method known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The extraction solvent is preferably added in an amount of 1 to 20 times the weight of the lily, more preferably 5 to 15 times, and the extraction temperature is preferably 80 to 110°C, but is not limited thereto. The extraction time is preferably 0.5 to 10 hours, and more preferably 0.5 to 5 hours, but is not limited thereto. In the above method, the drying in step (3) is preferably performed by reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

[0030] The above lily may be any part of the lily, preferably the scaly stem, but is not limited thereto.

[0031] The above muscle disease is preferably a muscle disease caused by muscle dysfunction, muscle atrophy, muscle wasting or muscle degeneration, and more preferably atony, muscular atrophy, muscular dystrophy, myotonia, rigid spinesyndrome, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Pompe Disease, Canavan disease, dystonia, muscular dystrophy, myasthenia, cachexia, sarcopenia, muscle fatigue, myasthenia gravis, hypotonia, muscular weakness, inflammatory myopathy, disuse atrophy, spinal It is one of, but not limited to, spinal muscular amyotrophy and spinobulbar muscular atrophy (Werdnig-Hoffmann disease; Kugelberg-Welander disease).

[0032] The composition of the present invention may be prepared in any one dosage form selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, but is not limited thereto. The composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-described active ingredient, and may be in various oral or parenteral dosage forms. When formulated, the composition is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, and pills, and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, and aerosols. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin. For parenteral administration, it is preferable to select a method such as topical application to the skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, epidural, or intracerebrovascular injection.

[0033] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The level of the effective amount may be determined based on factors including the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be easily determined by those skilled in the art.

[0034] The dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity, and the daily dosage is 0.01 to 2,000 mg / kg based on the amount of anchovy extract, preferably 30 to 500 mg / kg, and more preferably 50 to 300 mg / kg, and can be administered 1 to 6 times a day. The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

[0035] In addition, the present invention provides a health functional food composition for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss, which contains a lily (Lilium lancifolium) extract as an active ingredient.

[0036] The above composition is preferably manufactured in any one dosage form selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto. When the health functional food composition of the present invention is used as a food additive, the active ingredient may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The amount of the active ingredient mixed may be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may also be used in an amount exceeding the above range.

[0037] There is no particular limitation on the type of the above food. Examples of foods to which the above-mentioned effective ingredient can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, etc., and include all health functional foods in the conventional sense. When the composition of the present invention is used as a health beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, just like a conventional beverage. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclotensin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin and aspartame can be used. The proportion of the above natural carbohydrates is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These components may be used independently or in mixtures. The proportion of these additives is not particularly important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

[0038] In addition, the present invention provides a veterinary composition for preventing or treating muscle disease, which contains a lily (Lilium lancifolium) extract as an active ingredient.

[0039] The veterinary composition of the present invention may further comprise suitable excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil. The veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using a method well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after being administered to an animal, and the formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc. The effective amount of the veterinary composition according to the present invention may be appropriately selected depending on the individual animal. It may be determined according to factors including the severity of the disease or condition, the sensitivity to the active ingredient of the present invention depending on the age, weight, health status or sex of the individual, the route of administration, the period of administration, other compositions combined with or used simultaneously with the composition, and other factors well known in the physiological or veterinary fields.

[0040] In addition, the present invention provides a feed additive for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss, which contains a lily (Lilium lancifolium) extract as an active ingredient.

[0041] The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. The term "feed" in the present invention may mean any natural or artificial diet, meal, etc., or ingredients of the meal, which are intended for or suitable for animals to eat, ingest, and digest. The type of the feed is not particularly limited, and feed commonly used in the relevant technical field may be used. Non-limiting examples of the feed include plant feeds such as grains, roots, fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal feeds such as proteins, inorganic substances, oils and fats, mineral substances, oils and fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.

[0042] In addition, the present invention provides a herbal medicine composition for preventing or treating muscle disease, which contains a lily (Lilium lancifolium) extract as an active ingredient.

[0043] The herbal medicine composition of the present invention means, but is not limited to, one manufactured according to a herbal medicine prescription.

[0044]

[0045] Hereinafter, the present invention will be described in detail by examples. However, the following examples are only illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0046]

[0047] Example 1. Preparation of lily extract

[0048] 500 g of lily was added with 5 liters of 70% (v / v) ethanol, and the mixture was refluxed at 80°C for 3 hours, extracted, and filtered. Afterwards, the lily extract was concentrated using a vacuum concentrator and freeze-dried using a freeze dryer, and used in the following examples.

[0049]

[0050] Example 2. Analysis of cell viability according to lily extract treatment

[0051] Myoblasts were cultured in 10% (v / v) FBS / DMEM (GM: growth medium). The cultured myoblasts were treated with the lily extract of the present invention at various concentrations (0, 50, 100, 200, 400 ㎍ / ㎖), cultured for 24 hours, and cell viability was measured using a CCK-8 assay.

[0052] In addition, myoblasts pretreated with lily extract for 12 hours were treated with H2O2 (0.25 mM), dexamethasone (DEX, 200 uM), and TNF-α (20 ng / ml), which induce muscle damage, respectively, and then cultured for 24 hours, and cell viability was measured using a CCK-8 assay.

[0053] As a result, as disclosed in Fig. 1, it was confirmed that cell viability was maintained up to a concentration of 400 μg / ml of lily extract, indicating no cytotoxicity.

[0054] In addition, the cell viability of myoblasts was reduced by approximately 20-30% by treatment with H2O2, dexamethasone (DEX), and TNF-α, but when pretreated with the lily extract of the present invention, the cell viability was maintained. From these results, it was confirmed that the lily extract of the present invention has a protective effect against myoblast death under various muscle damage conditions (Fig. 2).

[0055]

[0056] Example 3. Confirmation of changes in myotube cells following treatment with lily extract.

[0057] The effect of lily extract on morphological changes in differentiated myotubes under muscle damage conditions (oxidative stress, drugs, and inflammatory cytokines) was investigated. Myotubes were differentiated from C2C12 myoblasts by adding 2% HS (horse serum) / DMEM (Dulbecco's Modified Eagle Medium) and changing the medium every 2 days for a total of 5 days. After 5-day differentiation, the myotubes were pretreated with lily extract for 24 hours, and then treated with H2O2, DEX, and TNF-α for 40 hours each to induce myotube cell disintegration. After staining the myotubes with crystal violet staining reagent, morphological changes and myotube density of the myotubes were quantified.

[0058] As a result, as shown in FIGS. 3A to 5A, it was confirmed that the morphology of myotube cells was seriously damaged by treatment with H2O2, DEX, and TNF-α, whereas the morphological damage was alleviated when pretreated with the lily extract of the present invention.

[0059] The results of quantifying the density of myotube cells also confirmed that muscle damage was suppressed by treatment with lily extract (Figs. 3B to 5B).

[0060]

[0061] Example 4. Confirmation of the muscle protective effect of lily extract in a muscular dystrophy mouse model (in vivo)

[0062] (1) Design of experimental animals and muscular atrophy animal models

[0063] Nine-week-old C57BL / 6N male mice were purchased and acclimated for one week before use in the experiment. Lily ethanol extract (100 mg / kg or 300 mg / kg) and resveratrol (positive control, 200 mg / kg) were orally administered once daily for 10 days, followed by intraperitoneal injection of dexamethasone (DEX, 25 mg / kg) 30 minutes later. On the 10th day, 30 minutes after the final drug administration, the grip strength of the experimental animals was sequentially assessed.

[0064] On the 11th day, the experimental animals were sacrificed through intraperitoneal injection of an anesthetic (avertin), and plasma and muscle tissue were obtained.

[0065]

[0066] (2) Measurement of grip strength

[0067] A grip strength test was conducted to measure the grip strength of experimental animals. Grip strength was measured using a grip dynamometer (47200UB; Ugo Basile, Gemonio, Italy). Each group of animal models was held by the tail and allowed to grasp the device's rod. The maximum force exerted when the tail was pulled horizontally at a constant speed (2 cm / sec) until the mouse's grip was released was considered the grip strength. Five measurements were taken for each mouse, and the average value was calculated.

[0068] As a result, as disclosed in Fig. 6, it was confirmed that the grip strength was statistically significantly reduced by repeated dexamethasone administration, and that the grip strength reduction caused by dexamethasone was effectively recovered when dexamethasone and the lily extract of the present invention were orally administered together.

[0069]

[0070] (3) Muscle mass measurement

[0071] The changes in muscle mass of the tibialis anterior (TA) and gastrocnemius (GA) muscles by muscle type were confirmed by administration of dexamethasone and the lily extract of the present invention.

[0072] As a result, as disclosed in Fig. 7, muscle mass was statistically significantly reduced in the tibialis anterior (TA) and gastrocnemius (GA) muscles by dexamethasone administration. In the experimental group orally administered with the lily extract of the present invention, muscle mass was statistically significantly increased compared to the group administered dexamethasone alone.

[0073]

[0074] (4) Muscle H&E staining and CSA analysis

[0075] Muscle tissue from mice was prepared on microscope slides and stained with hematoxylin and eosin (H&E). After obtaining digital images at 100× magnification, the cross-sectional area (CSA) of at least 600 muscle fibers (approximately 600–1800) was quantitatively measured using Image J with the Cross-Section Analyzer plugin.

[0076] As a result, the muscle fiber cross-sectional area was statistically significantly reduced by dexamethasone treatment, and the muscle fiber distribution of the lily extract administration group of the present invention was similar to that of the normal group compared to the dexamethasone only administration group (Fig. 8A), and the muscle fiber cross-sectional area was statistically significantly increased (Fig. 8B).

Claims

1. A pharmaceutical composition for the prevention or treatment of muscle disease, comprising a lily (Lilium lancifolium) extract as an active ingredient.

2. A pharmaceutical composition for preventing or treating muscle disease, characterized in that the extraction solvent of the lily extract in paragraph 1 is any one selected from water, C1-C4 lower alcohol, and mixtures thereof.

3. A pharmaceutical composition for preventing or treating muscle disease, characterized in that the muscle disease in paragraph 1 is a muscle disease caused by decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration.

4. In the third paragraph, the muscle disease is atony, muscular atrophy, muscular dystrophy, myotonia, rigid spine syndrome, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Pompe disease, Canavan disease, dystonia, muscular dystrophy, myasthenia, cachexia, sarcopenia, muscle fatigue, myasthenia gravis, hypotonia, muscular weakness, inflammatory myopathy, disuse atrophy, spinal muscular amyotrophy, and spinal bulbar muscle A pharmaceutical composition for the prevention or treatment of a muscle disease characterized by being any one selected from among muscular atrophy (sphinobulbar muscular atrophy; Werdnig-Hoffmann disease; Kugelberg-Welander disease).

5. A pharmaceutical composition for preventing or treating muscle disease, characterized in that, in addition to the effective ingredient in paragraph 1, it further comprises a pharmaceutically acceptable carrier, excipient or diluent.

6. A pharmaceutical composition for preventing or treating muscle disease, characterized in that the composition is prepared in any one formulation selected from among capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols in the first paragraph.

7. A health functional food composition for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss, containing lily (Lilium lancifolium) extract as an active ingredient.

8. A health functional food composition for preventing or improving muscle strength enhancement, muscle growth, muscle differentiation, muscle regeneration, or muscle loss, characterized in that the composition is manufactured in any one formulation selected from powder, granules, pills, tablets, capsules, candies, syrup, and beverages in the 7th paragraph.

9. A veterinary composition for the prevention or treatment of muscle disease containing lily (Lilium lancifolium) extract as an active ingredient.

10. A feed additive containing lily (Lilium lancifolium) extract as an active ingredient for strengthening muscle, increasing muscle strength, differentiating muscle, regenerating muscle, or preventing or improving muscle loss.

11. A herbal medicine composition for the prevention or treatment of muscle disease containing lily (Lilium lancifolium) extract as an active ingredient.

Images